Skip to main content
Journal of Epidemiology and Global Health logoLink to Journal of Epidemiology and Global Health
. 2026 Jan 10;16(1):8. doi: 10.1007/s44197-025-00510-x

The Emergence and Characterization of SARS-CoV-2 Variant XFG (“Stratus”): Comparative Virological, Epidemiological, and Public-Health Perspectives

Leena E Azhar 1, Dania A Samkari 2, Ahmed M Hassan 2, Salma M Alsayed 3,4, Esam Ibraheem Azhar 2,5,✉
PMCID: PMC12827822  PMID: 41519993

Abstract

Background

SARS-CoV-2 continues to diversify under the selective pressure of population immunity, with recombination increasingly contributing to the emergence of new lineages. The recombinant lineage XFG (“Stratus”), detected in early 2025, has attracted attention because it combines genetic features from distinct Omicron descendants and has expanded across multiple regions.SARS-CoV-2 continues to diversify under the selective pressure of population immunity, with recombination increasingly contributing to the emergence of new lineages. The recombinant lineage XFG (“Stratus”), detected in early 2025, has attracted attention because it combines genetic features from distinct Omicron descendants and has expanded across multiple regions.

Objective

To synthesize the current virological, immunological, epidemiological, and clinical evidence on XFG, and to contextualize its public-health significance through comparison with the closely related Omicron-derived lineages JN.1 and NB.1.8.1.…

Approach

This narrative review integrates available molecular and immune data with surveillance observations and emerging clinical reports, translating technical findings into implications that are relevant for healthcare systems and the people they serve.

Key findings

Across available datasets, XFG shows modest immune escape and a moderate growth advantage, yet there is no signal of increased clinical severity compared with recent Omicron sublineages. Current evidence supports the continued effectiveness of vaccines and antivirals, reinforcing that incremental viral adaptation is compatible with stable clinical outcomes in immunologically experienced populations.

Conclusions

XFG exemplifies ongoing, “quiet” SARS-CoV-2 evolution—more consistent with antigenic fine-tuning than a shift toward greater virulence. For individuals, the practical message remains steady: stay updated with vaccination when eligible and seek timely care when at higher risk. For health systems, sustained genomic surveillance, targeted protection of vulnerable groups, and measured risk communication remain central to resilient coexistence with SARS-CoV-2.

Keywords: SARS-CoV-2 variants, Omicron recombinants, XFG (Stratus), JN.1, NB.1.8.1, Immune escape, Genomic surveillance, Public-health preparedness

Introduction

SARS-CoV-2, the causative agent of COVID-19, continues to evolve despite widespread immunity and declining mortality rates. The virus’s adaptability driven by vaccination, infection history, and global movement—has made evolutionary monitoring an essential part of public health [1–3]. The Omicron lineage, which first appeared in 2021, has since diversified into numerous sub-lineages (BA.1–BA.5, XBB, JN.1) that illustrate the virus’s capacity for fine-tuned immune evasion rather than renewed virulence [4–7].

Recombination has now emerged as a key evolutionary mechanism, occurring when two variants co-infect a single host and exchange genetic material. This process occasionally produces hybrid lineages that combine adaptive advantages from each parent [8].

In January 2025, a new recombinant lineage XFG, nicknamed “Stratus” was identified from parental lineages LF.7 and LP.8.1.2 [1, 9]. The earliest sample was collected on 27 January 2025, and by 25 June 2025, the World Health Organization (WHO) had classified it as a Variant Under Monitoring (VUM). XFG’s spike protein carries several notable substitutions, including S31P, K182R, R346T, V445R, F456L, N487D, Q493E, and T572I, many within receptor-binding and antigenic domains. These changes may slightly alter receptor affinity and antibody recognition [10–12].

This review examines the scientific and human context of XFG’s emergence, its genomic structure, prevalence, immune characteristics, and implications for public-health preparedness while comparing it to JN.1 and NB.1.8.1, two recent Omicron descendants.

Virological and Molecular Features

Genetic Background and Mutational Profile

XFG represents a true recombinant lineage, merging portions of the genomes of LF.7 and LP.8.1.2. Such recombination can accelerate viral adaptation by combining advantageous mutations from each parental lineage [1, 11]. XFG’s spike-protein mutations particularly V445R, F456L, N487D, and Q493E cluster around the receptor-binding domain, a region central to host-cell attachment and antibody recognition [10–13].

Comparison with JN.1 and NB.1.8.1

For comparison, JN.1, a descendant of BA.2.86, was first detected on 25 August 2023 and designated a Variant of Interest by the WHO on 18 December 2023 [2, 14]. It harbored notable spike substitutions such as L455S, associated with partial immune escape. NB.1.8.1, identified on 22 January 2025 and listed as a Variant Under Monitoring on 23 May 2025, evolved from JN.1 and introduced further mutations including T22N, F59S, G184S, A435S, V445H, T478I, and Q493E [3, 15].

Functional assays indicate that XFG demonstrates a 1.9-fold reduction in neutralization titers relative to LP.8.1.1, compared with 1.5–1.6-fold for NB.1.8.1 [1, 10, 16]. These modest differences suggest a small fitness advantage through mild immune escape without compromising vaccine-induced protection. Collectively, these findings illustrate incremental evolution rather than a dramatic shift in virulence or transmissibility of an evolutionary trajectory consistent with Omicron’s broader pattern of adaptive refinement.

A comparative summary of the molecular, immunological, and clinical characteristics of the three lineages is presented in Table 1, highlighting both their shared ancestry and adaptive divergence. JN.1’s emergence in 2023 marked the start of a succession of subvariants that balanced transmissibility with immune evasion. NB.1.8.1 and the subsequent recombinant XFG, arising in early 2025, exemplify this ongoing antigenic fine-tuning. All three demonstrate similar reductions in neutralization (≈ 1.5–1.9-fold) and no evidence of increased clinical severity.

Table 1.

Comparative virological and clinical features of SARS-CoV-2 variants JN.1, NB.1.8.1, and XFG (“Stratus”)

Feature JN.1 NB.1.8.1 XFG (“Stratus”) References
Earliest documented sample 25 Aug 2023 22 Jan 2025 27 Jan 2025 [2, 5]
WHO designation VOI (18 Dec 2023) VUM (23 May 2025) VUM (25 Jun 2025) [1–3, 5]
Genetic origin BA.2.86 descendant JN.1 descendant Recombinant (LF.7 + LP.8.1.2) [1–3, 14]
Key spike substitutions L455S T22N, F59S, A435S, V445H, T478I, Q493E S31P, K182R, R346T, V445R, F456L, N487D, Q493E, T572I [1, 2, 14–17]
Neutralization reduction (vs. LP.8.1.1) ≈ 1.6 × ≈ 1.5–1.6 × ≈ 1.9 × [1, 2, 14, 14, 15, 17]
Transmission trend High (global dominance 2024) Rising (spring 2025) Rapid expansion (summer 2025) [1, 4, 5]
Clinical severity Mild–moderate Mild–moderate No increase in severity [1, 2, 4, 12, 13]
Public health risk (WHO) Low Low Low [1–5]

Caption: Comparative genomic, epidemiologic, and clinical characteristics of JN.1, NB.1.8.1, and XFG variants as summarized from WHO, ECDC, and peer-reviewed data (2023–2025)

From a human centered perspective, Table 1 underscores a critical point: viral evolution is not driven by intent but by persistence. SARS-CoV-2 continues to adapt to the collective immunity shaped by vaccination and prior infection. Understanding this interplay helps clinicians and policymakers interpret genomic changes calmly as part of a continuing process of coexistence, guided by vigilance, equity, and transparent communication [1–5, 12, 13].

Epidemiology and Global Spread

By June 2025, the recombinant SARS-CoV-2 lineage XFG had been identified in 38 countries, with 1,648 genome sequences uploaded to GISAID for epidemiological week (EW) 22 (26 May–1 June 2025) [1]. During that week, XFG constituted approximately 22.7% of global submissions, a marked rise from 7.4% just four weeks earlier (EW 19). In the United States, it accounted for around 14% of sequenced infections by 21 June 2025 [10].

The World Health Organization (WHO) described XFG as having a moderate growth advantage, though the assessment carried low confidence given the limited dataset available at the time [1]. The variant’s expanding prevalence is best explained by modest immune escape, waning population immunity, and seasonal behavioral factors that facilitate transmission. A similar yet slower pattern of spread was observed for NB.1.8.1 across Europe, reflecting comparable evolutionary pressures within post-Omicron lineages [5].

This evolutionary rhythm mirrors the broader post-2023 SARS-CoV-2 landscape, where newly emergent variants tend to represent gradual antigenic drift rather than the appearance of fundamentally new viral phenotypes. The virus continues to evolve within the contours of existing population immunity, adjusting incrementally rather than transforming abruptly.

From a public-health perspective, this progression reinforces the need for sustained genomic surveillance and measured risk communication. Variant evolution has become an expected feature of SARS-CoV-2 ecology; what matters now is interpreting these changes through evidence, transparency, and preparedness rather than alarm.

Figure 1 depicts the chronological trajectory of variant emergence from JN.1 in late 2023, to NB.1.8.1 in early 2025, and subsequently to XFG (“Stratus”) by mid-2025 [1–5]. JN.1 established the genetic foundation upon which later sub-lineages diversified; NB.1.8.1 extended that lineage through additional spike mutations; and XFG emerged as a recombinant hybrid bridging multiple Omicron branches. The overlapping timelines highlight the continuity of viral adaptation, a process defined more by persistence than disruption.

Fig. 1.

Fig. 1

Chronological timeline of detection, WHO designation, and global expansion of SARS-CoV-2 variants JN.1, NB.1.8.1, and XFG (“Stratus”), 2023–2025

The figure illustrates the sequential emergence and recognition of key Omicron-derived SARS-CoV-2 lineages over the period August 2023 – June 2025. JN.1 (light blue) was first detected in August 2023 and designated a Variant of Interest by the World Health Organization (WHO) in December 2023. NB.1.8.1 (medium blue), a JN.1 sub-lineage, appeared in January 2025 and was classified as a Variant Under Monitoring in May 2025. The recombinant XFG (“Stratus”) lineage (dark blue) emerged in June 2025 and showed a moderate growth advantage associated with modest immune escape. The staggered but overlapping timelines highlight the evolutionary continuity of SARS-CoV-2 adaptation gradual antigenic drift within an established Omicron framework underscoring the need for sustained genomic surveillance and measured public-health communication.

Immune, Vaccine, and Therapeutic Implications

Neutralization data suggest that XFG reduces antibody sensitivity by approximately 1.9-fold compared to LP.8.1.1 [1, 10, 16]. While measurable, this level of reduction is modestly smaller than the drops seen during the emergence of BA.1 or XBB. WHO and ECDC assessments both conclude that existing vaccines continue to provide strong protection against severe illness and hospitalization [1, 5, 8].

Importantly, antiviral drugs targeting non-spike proteins (e.g., nirmatrelvir/ritonavir, remdesivir, molnupiravir) retain full efficacy, as XFG’s mutations are confined to the spike gene [5]. Likewise, no disruptions have been reported in diagnostic assays PCR primers and antigen-test epitopes remain unaffected [10].

From a policy perspective, maintaining booster coverage in vulnerable groups remains the most impactful measure. The 2024 WHO guidance on monovalent XBB.1.5-based vaccines continues to offer adequate cross-protection, reducing hospitalization risk across newer Omicron descendants, including XFG [8, 18].

Clinical Presentation and Severity

Available reports confirm that XFG infections resemble those of previous Omicron subvariants. Symptoms typically include sore throat, cough, nasal congestion, fatigue, and headache; fever tends to be low-grade, while loss of smell or taste remains rare [10, 11]. A slight increase in hoarseness or raspy voice has been observed in small clusters, though not statistically confirmed.

Crucially, no evidence indicates that XFG causes more severe disease than its predecessors. Hospitalization and mortality rates remain stable compared to JN.1 and NB.1.8.1 [1, 2, 5]. The WHO’s risk assessment concluded that “XFG carries no signal of increased clinical severity” [1].

This consistency highlights a positive shift: widespread immunity has decoupled infection rates from severe outcomes, transforming COVID-19 from a crisis to a manageable respiratory illness in most populations.

Public-Health Implications and Humanized Perspective

The emergence of XFG underscores the continued necessity of genomic surveillance. Its recombinant nature reflects SARS-CoV-2’s capacity to exploit lapses in monitoring, particularly when sequencing efforts decline [9, 10]. Transparent data sharing remains essential for detecting recombination events before they spread widely.

Equally important is communication. After years of pandemic fatigue, the public often greets variant news with anxiety or apathy. Health authorities must adopt a measured tone emphasizing vigilance without alarm. Messaging that stresses continuity rather than crisis (“vaccines still work,” “no increase in severity”) helps sustain public trust and engagement.

Vaccination equity also remains a moral and epidemiological imperative. Regions with low booster coverage are more vulnerable to hospital surges, even from variants with mild immune escape. Ensuring equitable access and combating misinformation are therefore central to maintaining global stability [5, 10, 19].

In human terms, XFG symbolizes the transition from pandemic response to enduring coexistence. Its rise did not trigger panic, but it reminded us that preparedness must persist not in emergency mode, but as a normal function of resilient health systems.

Limitations and Knowledge Gaps

Much of what is known about XFG derives from genomic surveillance and pseudovirus assays; large-scale clinical and vaccine-effectiveness data are still forthcoming [1, 9]. Regional disparities in sequencing may skew prevalence estimates, and immune heterogeneity complicates interpretation of neutralization studies.

Further research should explore XFG’s recombinant fitness, its potential for immune persistence, and cross-reactivity with future vaccines. Longitudinal monitoring and neutralization mapping across regions will be crucial to determining whether XFG represents an evolutionary endpoint or a bridge to new recombinant forms [15, 20].

Conclusion

The SARS-CoV-2 variant XFG (“Stratus”) illustrates the virus’s quiet adaptability in a world learning to live alongside it. With its recombinant backbone, modest antigenic drift, and global presence, XFG epitomizes a virus that continues to evolve within human-imposed limits [21, 22].

Current evidence shows no increase in severity, no therapeutic resistance, and no diagnostic escape. Vaccines remain protective, and clinical outcomes are stable. For individuals, the message is simple: stay vaccinated, stay informed, and stay calm. For public health institutions, vigilance not alarmism remains the path forward. XFG is not a new threat, but a reminder that adaptation both viral and human—is ongoing.

Acknowledgements

The authors acknowledge the generous charitable donation from the Late Sheikh Ibraheem Ahmed Azhar in the fund as a contribution to the scientific research community.

Author Contributions

All authors jointly conceptualized the editorial, contributed to drafting and critical revision, and approved the final manuscript.

Funding

No external funding was received for this work.

Data Availability

No datasets were generated or analysed during the current study.

Declarations

Ethical Approval

Not applicable (no human or animal subjects).

Competing interests

The authors declare no competing interests.

Footnotes

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

  • 1.World Health Organization. Initial risk evaluation for SARS-CoV-2 variant under monitoring: XFG (Stratus). Geneva: WHO; 2025. Jun 25. [Google Scholar]
  • 2.World Health Organization. Risk evaluation for SARS-CoV-2 variant under monitoring: NB.1.8.1. Geneva: WHO; 2025. May 23. [Google Scholar]
  • 3.World Health Organization. Updated risk evaluation of SARS-CoV-2 variant JN.1. Geneva: WHO; 2024. Apr 15. [Google Scholar]
  • 4.World Health Organization. Tracking SARS-CoV-2 variants. Geneva: WHO; 2025. [Google Scholar]
  • 5.European Centre for Disease Prevention and Control. Epidemiological update: SARS-CoV-2 and NB.1.8.1 variant assessment. Stockholm: ECDC; 2025. Jun 13. [Google Scholar]
  • 6.European Centre for Disease Prevention and Control. Weekly communicable disease threats report, week 40 (27 Sep–3 Oct 2025). Stockholm: ECDC; 2025. [Google Scholar]
  • 7.Lu Y, Zhao J, Zhang W, et al. The rising SARS-CoV-2 JN.1 variant: evolution, infectivity and immune characteristics. Mol Cell Oncol. 2024;11(1):e675. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.World Health Organization. Statement on the antigen composition of COVID-19 vaccines. Geneva: WHO; 2024. Apr 26. [Google Scholar]
  • 9.World Health Organization. South-East Asia regional Office. Epidemiological bulletin 2025_13. New Delhi: WHO SEARO; 2025 Jul. p. 1.
  • 10.Center for Infectious Disease Research and Policy. WHO adds XFG to SARS-CoV-2 variants under monitoring. Minneapolis (MN): CIDRAP; 2025. Jun 27. [Google Scholar]
  • 11.Center for Infectious Disease Research and Policy. US COVID-19 activity falling; XFG still predominant, wastewater suggests. Volume 3. Minneapolis (MN): CIDRAP; 2025 Oct.
  • 12.Center for Infectious Disease Research and Policy. US COVID-19 levels continue slight upward trend (XFG and NB.1.8.1 context). Minneapolis (MN): CIDRAP; 2025 Jul. p. 25.
  • 13.TIME. What to know about the new COVID-19 variant XFG (Stratus). New York: TIME; 2025 Jul.
  • 14.Geddes L. Eight things you need to know about the new nimbus and stratus COVID-19 variants. VaccinesWork (Gavi). 2025 Jun 16.
  • 15.Jian F, Li Y, Chen Z, et al. Evolving antibody response to SARS-CoV-2 antigenic shift from XBB to JN.1. Nature. 2025;628. 10.1038/s41586-024-08315-x. online ahead of print. [DOI] [PMC free article] [PubMed]
  • 16.Tsujino S, Wada Y, Morioka T, et al. Evolution of BA.2.86 to JN.1 reveals functional changes in Spike and viral properties. J Virol. 2025;99:e00908–25. 10.1128/jvi.00908-25. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Li P, Zhang M, Hu J, et al. Neutralization and Spike stability of JN.1-derived subvariants. mBio. 2025;16:e00464–25. 10.1128/mbio.00464-25. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Link-Gelles R, McMorrow M, Dascomb K, et al. Early estimates of 2023–2024 monovalent XBB.1.5 COVID-19 vaccine effectiveness. MMWR Morb Mortal Wkly Rep. 2024;73(4):1–8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.World Health Organization. Global risk assessment of emerging SARS-CoV-2 lineages. Geneva: WHO; 2025 Aug.
  • 20.Hu Y, Lin Y, Zhang R, et al. Comparative analysis of replication and immune evasion of BA.2.86/JN.1 family subvariants. Front Immunol. 2025;16:1565934. 10.3389/fimmu.2025.1565934. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Li P, He D, Yang S, et al. Distinct patterns of SARS-CoV-2 BA.2.87.1 and JN.1 variants in neutralization resistance and fitness. mBio. 2024;15:e00751–24. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.World Health Organization. COVID-19 variants dashboard (WHO Data). Geneva: WHO; 2025. [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Data Availability Statement

No datasets were generated or analysed during the current study.


Articles from Journal of Epidemiology and Global Health are provided here courtesy of Springer

RESOURCES